Squalene synthase (SSN, EC 2.5.1.21), a major enzyme in the sterol biosynthetic pathway, catalyses an unusual head-to-head reductive dimerization of two molecules of farnesyl-pyrophosphate (FPP) in a two-step reaction to form squalene. FPP serves as a metabolic intermediate in the formation of sterols, dolichols, ubiquinones and farnesylated proteins. Here, we report cloning, expression and purification of a catalytically active recombinant squalene synthase of Leishmania donovani (LdSSN). The pH and temperature optima of LdSSN were 7.4 and 37 1C, respectively. Biochemical studies revealed that the K m and V max for the substrate FPP were 3.8 mM and 0.59 nM min À1 mg À1 and for NADPH were 43.23 mM and 0.56 nM min À1 mg À1 . LdSSN was found to be sensitive towards denaturants as manifested by a loss of enzyme activity at the concentration of 1 M urea or 0.25 M guanidine hydrochloride. Zaragozic acid A, a potent inhibitor of mammalian SSN, was also a competitive inhibitor of recombinant LdSSN, with a K i of 74 nM. This is the first report on the purification and characterization of full-length recombinant SSN from L. donovani. Studies on recombinant LdSSN will help in evaluating this enzyme as a potential drug target for visceral leishmaniasis.
Introduction
Protozoan parasites of the genus Leishmania cause severe diseases that threaten human beings, both for the high mortality rates involved and the economic loss resulting from morbidity, primarily in tropical and subtropical areas (Das et al., 2008) . As declaration is compulsory in only 32 of the 88 countries affected by leishmaniasis, a substantial number of cases are never recorded. In fact, 2 million new cases (1.5 million cutaneous and 500 000 visceral) are considered to occur annually, with an estimated 12 million people presently infected worldwide (http://www.who.int/ leishmaniasis/burden/en/). No effective vaccines are available against Leishmania infections as yet and treatment relies solely on chemotherapy, with pentavalent antimonials as first-line drugs and amphotericin B and pentamidine as second-line agents (Herwaldt, 1999; Murray, 2000; Handman, 2001) . Miltefosine is the first recognized oral treatment for leishmaniasis, but resistance to miltefosine may emerge easily during treatment due to single point mutation (Seifert et al., 2007) . There is a pressing need for the identification of novel drug targets, virulence factors and development of vaccines to expand our understanding of the prevention and treatment of leishmaniasis. The enzymes of the sterol biosynthesis pathway are attractive targets for the specific treatment of leishmaniasis as the aetiological agents of the disease require endogenous ergosterol and other alkylated sterols for growth and survival (Urbina et al., 2002) . The formation of squalene is the first committed step in sterol biosynthesis and a blockade at this level of the pathway does not affect the production of other essential isoprenoids and the accumulated isoprenoid intermediates (farnesyl pyrophosphate and precursors) can be readily metabolized and excreted (Gonzalez-Pacanowska et al., 1988) . For these reasons, SSN is currently under intense study as a possible target for cholesterol-lowering agents in humans (Bergstrom et al., 1995; Watson & Procopiou, 1996) . Significant advances have been made in the understanding of the reaction mechanism of the vertebrate SSN (Mookhtiar et al., 1994) and recently, the crystal structure of a soluble, fully active form of the human enzyme was reported (Pandit et al., 2000) . Overexpression or selection studies in Leishmania major (Cotrim et al., 1999) have shown that the expression of SSN is strongly activated in these cells in the presence of sterol biosynthesis inhibitors. Quinuclidines inhibit the leishmanial SSN, disrupt endogenous sterol biosynthesis and cause the inhibition of the growth of the leishmanial parasite (Lorente et al., 2005; Rodrigues et al., 2005; Cammerer et al., 2007) . E5700, an inhibitor of SSN, has been tested in a murine model of chagas disease and is able to provide complete protection against death and completely suppress parasitimia (Urbina et al., 2004; Rodrigues et al., 2008) . Studies related to structure-function relationship may lead to a better understanding of this potential drug target.
We have cloned, overexpressed the Leishmania donovani SSN gene in pET-28(a) transformed in Escherichia coli and designated as LdSSN. This recombinant L. donovani SSN enzyme was purified and biochemically characterized. Here, we describe, for the first time, partial purification of fulllength LdSSN through anion exchange chromatography followed by hydrophobic interaction chromatography and finally validated by Western blot. Biochemical properties such as pH optimum, thermal stability and the effect of denaturants on LdSSN are reported here.
Materials and methods

Chemicals and reagents
Farnesyl pyrophosphate (FPP) unlabelled, squalene unlabelled, 2-mercaptoethanol, NADPH, phenylmethylsulfonyl fluoride (PMSF) and Zaragozic acid A (microbial origin) were obtained from Sigma-Aldrich. Restriction enzymes used for cloning were obtained from MBI, Fermentas. Monoclonal His-antibody and Ni-NTA superflow were obtained from Qiagen. pGEM-T Easy cloning vector was purchased from Promega. Expression vector pET-28(a) was obtained from Novagen; Tritiated FPP was obtained from ARC. Q-Sepharose, Phenyl Superose, ECL Western blotting detection reagents were obtained from Amersham. All other biochemicals were of the highest grade available.
Leishmania donovani culture
The WHO reference strain of L. donovani (MHOM/IN/80/ Dd8) was obtained from Imperial College London (UK) and maintained in vitro as promastigotes in RPMI 1640, supplemented with 10% heat-inactivated fetal bovine serum containing 40 mg mL À1 gentamycin at 25 1C.
Bacterial strains and plasmid vectors
The TA cloning vector pGEM-T Easy was used to clone the PCR product, and the pET-28(a) vector having both N and C terminal His 6 -tag was used for expression of the recombinant protein. The recombinant plasmids were transformed into E. coli BL21 (DE3) cells for expression.
Construction of expression vector pET-28(a)-LdSSN
PCR primers 5 0 -CATATGGGGTTCTTCTCGGATTCGG TAG-3 0 (forward) and 5 0 -AAGCTTCGCGTGGCCGGCA ATCTCCTTG-3 0 (reverse) with NdeI restriction site at the forward and HindIII at the reverse end shown as underlined were designed based on the L. major SSN gene (U30455) sequence. Amplification of the SSN gene was carried out using genomic DNA of L. donovani as template. The reaction mixture contained 50 ng of genomic DNA, 1.5 U Taq polymerase, 0.5 mM primer (each) and 200 mM each dNTPs in 50 mL PCR reaction mixture volume. After initial denaturation at 94 1C for 3 min, the PCR reaction was programmed for 30 cycles, with each cycle including denaturation at 94 1C for 30 s, 50 1C annealing temperature for 1 min and extension at 72 1C for 2 min. There was a final extension at 72 1C for 10 min. The amplified product after gel purification was cloned in the pGEM-T-Easy vector and transformed in E. coli DH5a competent cells. Nucleotide sequencing of the recombinant construct was carried out in both directions to confirm the sequence of the amplicon and the sequence was submitted to NCBI GenBank. The recombinant construct was digested with restriction endonuclease NdeI and HindIII and subcloned into the prokaryotic expression vector pET-28(a) for overexpression and purification of recombinant LdSSN.
Phylogenetic analysis and multiple sequence alignment
SSN genes of diverse species at the level of the deduced amino acid sequence from Swiss prot or protein data bank (http://www.expasy.org/sprot/) were aligned with CLUSTALW, followed by the generation of a phylogenetic tree.
Expression and purification of Ld SSN
The recombinant construct pET-28 (a)-LdSSN was used to transform competent E. coli BL21 (DE3 
Ion exchange chromatography
The cleared supernatant was applied to a 2 cm Â 10 cm column packed with an anion-exchanger, Q-Sepharose, previously equilibrated with buffer A. The flow through was collected and passed five to six times from the column. The protein fraction bound to the matrix (including the target protein) was eluted with 100 mL of a linear 0-1 M NaCl gradient, prepared in the same buffer. The fractions were then run on a 10% sodium dodecyl sulphate (SDS) gel to determine which fractions contain the full-length squalene synthase. The fractions showing SSN activity were pooled and applied on a phenyl superose column for further purification. volume of the reaction was 200 mL. After incubation at 37 1C for 5 min, 40 mL of 10 M NaOH was added, followed by 10 mL of a mixture (50 : 1) of 70% ethanol and squalene. The resulting mixtures were mixed vigorously by vortexing, and then 10-mL aliquots were applied to 2.5 Â 10-cm channels of a silica gel thin-layer chromatogram, and the newly formed squalene was separated from unreacted substrates by chromatography in toluene-ethyl acetate (9 : 1). The region of each chromatogram from 2 cm below the squalene band (R f = 0.74) to the top of the chromatogram was removed and immersed in liquid scintillation fluid and assessed for radioactivity, measuring the amount of FPP converted to squalene using a Pharmacia LKB liquid scintillation counter. The protein concentration was measured using the Lowry method, with bovine serum as a standard. Four controls were run parallel with the SSN activity assay, i.e. without substrate, without enzyme, only scintillation fluid and only pET-28(a) in BL21 (DE3) cells.
Separation by hydrophobic interaction
Thermal stability
Thermal stability of LdSSN was determined by measuring the activity after incubating LdSSN at different temperatures ranging from 30 to 70 1C, with an interval of 10 1C for 10 min. The samples were then cooled to room temperature and enzyme activity was measured as mentioned above.
pH dependence
For studying the effect of pH on enzyme activity, the reaction buffer of pH range from 4.0 to 9.0 were taken and an enzyme assay was performed. The pH range of different buffers taken were sodium acetate buffer, 4.0-5.5; 2-(Nmorpholino)ethanesulfonic acid, 5.7-6.4; MOPS-Na buffer, 6.5-8.0; and glycine-NaOH buffer, 9.0-10.
Effects of denaturants
For studying the effect of denaturants on SSN activity, the enzymatic activity was determined by measuring the residual activity after incubating the LdSSN at different concentrations of urea and GdmCl (1-4 M with urea and 0.1-1 M with GdmCl) for 4 h.
Inhibitory studies with zaragozic acid A
The 50% inhibitory concentration of zaragozic acid A (microbial origin) for LdSSN was determined by measuring the conversion of FPP to squalene in the presence of different concentrations of zaragozic acid A. [1-3 H] FPP (1 mM; 50 mCi 3 H mmol À1 ) and 0-160 nM zaragozic acid A were incubated with 80 mg of LdSSN for 10 min and then added to the reaction mixture to obtain a final volume 200 mL. To determine the mode of zaragozic acid A inhibitory action against LdSSN, initial velocity studies were performed using various concentrations of Zaragozic acid A at different fixed concentrations of FPP. The assays were performed as described above.
Results and discussion
Sequence analysis of Ld SSN Genes encoding SSN have been isolated from many sources, such as fungi (Fegueur et al., 1991; Jennings et al., 1991; LoGrasso et al., 1993; Zhang et al., 1993) , bacteria (Lee & Poulter, 2008) , animals (McKenzie et al., 1992) , Arabidopsis thaliana (Nakashima et al., 1995) and plants (Hanley et al., 1996; Hata et al., 1997; Devarenne et al., 1998; Lee et al., 2002) . The enzyme is monomeric and has been reported to be associated with the endoplasmic reticulum at least in most eukaryotes. The generation of high quantities of soluble enzyme for inhibitor screening was attempted using a strategy that proved to be successful with other eukaryotic SSNs. Due to unavailability of L. donovani genome sequence, primers for the amplification and cloning of the squalene synthase gene were designed on the basis of the L. major genome database available (Britto et al., 1998; Ravel et al., 1999 ). An ORF of 1245 base pairs encoding 415 amino acids of LdSSN was amplified from L. donovani gDNA (Fig. 1a) . Authenticity of the gene was confirmed by DNA sequencing. The nucleotide sequence of LdSSN was submitted to GenBank under accession no. AM229310. The LdSSN coding region was found to be enriched in G1C residues (59%) in comparison with A1T residues (41%) like other leishmanial genes. The LdSSN gene is considerably conserved and a comparative analysis of the amino acid sequences reveals 97% homology with L. major, 57% with Trypanosoma cruzi, 45% with mouse and 44% with human. The sequence analysis of the encoded LdSSN protein showed the presence of 192 basic amino acids (K, R, H) and 260 acidic amino acids (D, E, B, N, Q, Z). The predicted isoelectric point (pI) of the protein was 5.73. The two signature sequences of squalene synthase were present at positions 71-75 and 211-215. As shown in CLUSTAL W alignment (Fig. 2) , all of the conserved residues described to be involved in catalysis (Pandit et al., 2000) (Fig. 1b) . Squalene synthase of L. major and L. donovani are very close to each other. The SSN of trypanosomatids is closer to prokaryotic SSN and mammalian SSN than the plant SSN. Escherichia coli is devoid of squalene synthase enzyme .
Expression and purification of Ld SSN
Recombinant plasmid pET-28 (a)-LdSSN was introduced in various E. coli strains such as Rosetta, Codon plus, BL21(DE3) and Tuner, but it was observed that recombinant LdSSN expressed mostly as inclusion bodies. Because one of the goals of the present work was to confirm the correct assignment to the gene encoding LdSSN, efforts were made to express recombinant L. donovani SSN in its soluble, active form avoiding unfolding and refolding protocols because they do not always result in greater yields of biologically active proteins. Several Leishmania proteins are reported to be insoluble in nature and tend to form inclusion bodies upon expression in prokaryotic hosts, for example, methionine adenosyl transferase (MAT 2) of L. donovani (PerezPertejo et al., 2003) , glucose-regulating protein 94 (GRP 94) of Leishmania infantum (Larreta et al., 2000) , adenylate kinase 2 of L. donovani , cysteine protease type A and B (CPA and CPB) genes of L. infantum (Rafati et al., 2003) . In practice, it is usually worthwhile to test several different vector/host combinations to obtain the best possible yield of protein in its desired form. Hence, a number of commercially available strains of E. coli host cells and expression vectors were tested in an attempt to produce LdSSN in the soluble form. Screening of experimental conditions were carried out to obtain high yields of recombinant protein, including growth temperature, medium type and hours of growth after IPTG induction.
For maximum overexpression of SSN protein in the soluble fraction, various parameters were standardized viz.
E. coli host strains, IPTG concentrations, incubation temperatures before and after induction and incubation period after induction. Because the pET-28a-SSN recombinant vector has T7 promoter, various hosts compatible with T7 promoter viz. BL21 (DE3), Rosetta and codon plus cells were attempted for the expression of soluble SSN protein.
The maximum solubility of SSN protein was found in BL21 (DE3) cells as compared with Rosetta and codon plus cells; therefore, further expression of recombinant SSN protein was carried out in BL21 (DE3) cells. IPTG concentrations varying from 0.1 to 1 mM were attempted so as to observe the amount of expressed SSN protein. However, no difference in the amount of expressed protein was observed with the above used concentrations. 0.1 mM IPTG concentration was used for protein induction and overexpression studies. Addition of 4 0.1 mM IPTG to the cultures did not lead to further increase in the amount of overexpressed recombinant LdSSN. The level of expression of recombinant LdSSN was tested under various temperatures ranging from 20 to 37 1C. At temperatures 37, 30 and 28 1C, the recombinant SSN protein was expressed at a significant level, but all the expressed protein appeared as inclusion bodies. Reducing the temperature to 20 1C resulted in the expression of the recombinant protein in a soluble form; however, below 20 1C, the solubility of the protein was increased but the total amount of expressed SSN protein was also decreased, and therefore, in further studies, BL21 (DE3) cells were induced at 20 1C with 0.1 mM IPTG. The induction time was varied from 6 to 12 h. The amount of recombinant soluble SSN protein was increased from 6 to 12 h; therefore, in further studies, the induction time was extended to 12 h to obtain the maximum amount of soluble protein. The best suitable parameters selected resulted in nearly 30% of the recombinant protein in the soluble fraction, whereas most of the protein was found in inclusion bodies. Initially, several attempts were made to purify the protein by Ni-NTA column chromatography but the desired protein failed to bind with the Ni-NTA column, suggesting that the His-tag was not free for the matrix, that is it may be possible that it was buried inside during the folding process. There is still no report on the purification of full-length squalene synthase by Ni-NTA chromatography, and so the recombinant protein was purified by Q-Sepharose followed by phenyl superose and was analysed by 10% SDS-PAGE (Fig. 3a) . The recovery of the enzyme activity in the various steps of its purification procedure is presented in Table 1 . Uninduced culture and BL21 (DE3) E. coli cells transformed with the pET-28(a) vector without the SSN gene were used as control. The specificity of the protein was further validated by Western blot by probing it with His antibodies because the expressed protein has a His 6 -tag attached to its Cterminal. The His antibodies specifically binds with Hisexpressed protein in the total cell lysate, pellet, supernatant and partially purified samples, while no cross-reactivity was detected in negative controls, which confirms the expression of His-tag protein in samples (Fig. 3b) .
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Biochemical characterization of Ld SSN
To demonstrate that the overexpressed recombinant LdSSN protein actually has SSN activity, the conventional radioactive assay was performed using purified recombinant LdSSN protein. The pH dependence, thermal stability and effect of denaturants (urea and GdmCl) were studied on recombinant LdSSN protein. Similar to most other SSNs, LdSSN showed activity in alkaline pH (Belingheri et al., 1991; Shechter et al., 1992) . The pH optimum for the LdSSN was observed as 7.4, which was in comparison with trypanosomal, rat and daffodil SSN (Belingheri et al., 1991; Shechter et al., 1992; Sealey-Cardona et al., 2007) , but was slightly higher than the value of 7.2 reported for the yeast enzyme (Zhang et al., 1993) . Moreover, a plateau was observed in the region of pH 7-7.8. The enzyme retained 4 80% activity in the buffer range of MOPS NaOH (Fig. 4a) .
Thermal stability of SSN varies in different organisms. The temperature optimum may be as high as 60 1C in Thermosynechococcus elongatus BP-1 (Lee & Poulter, 2008) and as low as 37 1C in other organisms. LdSSN showed maximum activity at 37 1C, whereas it exhibited 83% and 88% activity at a temperature of 30 and 45 1C. LdSSN was found to be temperature sensitive as compared with other SSN, as it loses 85% of its activity at 60 1C (Fig. 4b) .
The effect of denaturants (urea and GdmCl) on LdSSN was assessed by incubating the enzyme at different concentrations of denaturants. The enzyme lost 81% and 86% of its activity at a concentration of 2 M urea and 0.3 M GdmCl, respectively ( Fig. 4c and d) . The enzyme loses 4 50% activity at a concentration of 1 M urea and 0.2 M GdmCl. The activity of the protein is more sensitive towards GdmCl than that of urea; this might be due to the ability of GdmCl to disturb the electrostatic interactions. The loss of activity can be due to unfolding of the enzyme, or due to disruption of the active-site microenvironment in the presence of denaturant molecules or due to preferential binding of molecules on the surface of LdSSN. The K m and V max for the substrate FPP were 3.8 mM and 0.59 nM min À1 mg À1 ( Fig. 5a and b) and were 43.23 mM and 0.56 nM min À1 mg À1 for NADPH ( Fig. 5c and d) . The kinetic parameters were compared with those reported previously for preparations of T. cruzi glycosomal and microsomal SSN (Urbina et al., 2002) and other recombinant enzymes. The resulting enzyme proved to be catalytically active and exhibited kinetic parameters highly similar to those obtained with the native enzyme in purified glycosomes and mitochondria from T. cruzi epimastigotes (Urbina et al., 2002) , albeit the K m for FPP was slightly higher. Likewise, the K m values were highly similar to those obtained for the truncated recombinant enzyme from yeast (LoGrasso et al., 1993) . Zaragozic acid A, a fungal metabolite, is a potent inhibitor of mammalian and fungal SSNs, which are thought to mimic farnesyl pyrophosphate and PSPP (Bergstrom et al., 1993 (Bergstrom et al., , 1995 Petras et al., 1999) . Zaragozic acid is a competitive inhibitor against FPP in rat SSN, which is followed by irreversible inactivation of the enzyme (Lindsey & Harwood, 1995) . When LdSSN activity was measured in the presence of $K m concentration of FPP, zaragozic acid A showed dose-dependent inhibition. Zaragozic acid A also showed inhibition with recombinant LdSSN, with a 50% inhibitory concentration of 100 AE 8 nM and Ki of 74 nM, which is in comparision with 95.5 AE 13.6 nM as reported in the squalene synthase of Thermosynechococcus elongatus BP-1 (Lee & Poulter, 2008) . Increasing the concentration of FPP resulted in an increase in the À 1/K m value but in no obvious change in the 1/V max value, indicating that FPP acts as a competitive inhibitor (Fig. 6) .
The results presented here represent the first step towards a better understanding of the properties of SSN in Leishmania. LdSSN is one of the major enzymes of the sterol biosynthetic pathway of Leishmania that has been characterized recently. Further studies will also help in determining the complexities of the sterol metabolic pathway in Leishmania. These primary studies will help in evaluating this enzyme as a drug target in Leishmania. If substantial difference with human and leishmanial SSN can be exploited, then the availability of leishmanial SSN in a catalytically active form should facilitate the search for antileishmanial agents directed at this enzyme. Experiments to screen highly effective LdSSN inhibitors are ongoing. 
